Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. We are focused on changing the narrative around skin diseases and making treatment a more efficient process for both physicians and patients. VP-102, our lead product candidate, is a drug-device combination topical therapy that has the potential to be the first product approved by the FDA to treat molluscum contagiosum (molluscum). If approved, VP-102 will be marketed in the United States under the conditionally accepted brand name, YCANTH. Results suggest that YCANTH, if approved, could potentially improve both clinical practice and patient outcomes by providing molluscum patients with a new treatment option.
Verrica has also entered a worldwide license agreement with Lytix Biopharma AS (“Lytix”) to develop and commercialize LTX-315 for dermatologic oncology conditions. Verrica intends to focus initially on basal cell and squamous cell carcinomas as the lead indication for development.
Verrica Pharmaceuticals, Inc.
10 N High St
West Chester, Pennsylvania 19380